Rectal Indomethacin in the Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients
| Status: | Archived |
|---|---|
| Conditions: | Gastrointestinal |
| Therapuetic Areas: | Gastroenterology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2009 |
| End Date: | December 2011 |
A Prospective, Randomized, Controlled Trial of Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients.
Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic
retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of
disorders of the pancreas and bile duct.
Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered
rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to
definitively determine whether rectally administered indomethacin (a non-steroidal
antiinflammatory drug)is effective at preventing pancreatitis after ERCP.
This study is a multi-center, randomized, placebo-controlled, double-blinded clinical trial
of rectal indomethacin in the prevention of post-ERCP pancreatitis in high risk patients.
We found this trial at
2
sites
Click here to add this to my saved trials
1500 E Medical Center Dr
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
(734) 936-4000
University of Michigan Health Systems The University of Michigan is home to one of the...
Click here to add this to my saved trials